Tevogen Bio Holdings Inc. (TVGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tevogen Bio Holdings Inc. on January 28, 2025. The Company is a Delaware corporation developing off-the-shelf, genetically unmodified precision T cell therapeutics to treat infectious diseases and cancers. It is classified as an emerging growth company.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The primary financial event disclosed is a non-dilutive capital infusion:
- Grant Received: $2,000,000
- Source: KRHP LLC, a New Jersey limited liability company.
- Relationship: KRHP is affiliated with the spouse of Dr. Manmohan Patel, an existing investor and beneficial owner of more than 5% of the Company's common stock.
Material Changes
The material change reported is the receipt of the $2,000,000 grant on January 28, 2025. This funding is designated to further the Company's development of its therapeutic pipeline. No other material changes to operations or financial position are detailed in this specific filing.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the grant and its intended use for product development. The filing does not contain updated financial guidance, specific risk factors, or contingencies beyond the standard disclosures associated with the grant transaction. The press release detailing the announcement is attached as Exhibit 99.1.
Investor Verification Checklist
- Verify the terms of the grant agreement with KRHP LLC to confirm if there are any repayment obligations, equity conversion rights, or milestones attached to the $2,000,000.
- Review the relationship between KRHP LLC and Dr. Manmohan Patel to understand the nature of the affiliated party transaction.
- Examine the attached press release (Exhibit 99.1) for specific details on how the funds will be allocated across the Company's development programs.
- Check subsequent filings for the impact of this grant on the Company's cash runway and burn rate.